Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 310 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Mesenchymal Stem Cell Clear all
Completed Phase 2 Interventional

Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

NCT00877903
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Prochymal®, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
32
States / cities
Gilbert, Arizona • Tucson, Arizona • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 1, 2026, 10:35 PM EDT
Active, not recruiting Phase 2 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells for Spinal Cord Injury Patients

NCT04520373
View directory record Official record
Conditions
Spinal Cord Injuries, Paralysis
Interventions
Best Medical Management: Occupational and Physical Therapy, Autologous, Adipose Derived Mesenchymal Stem Cells
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 1, 2026, 10:35 PM EDT
Completed Phase 1Phase 2 Interventional

Follow-up Study of Chondrogen® Delivered by Intra-Articular Injection Following Meniscectomy

NCT00702741
View directory record Official record
Conditions
Recovery Following Partial Medial Meniscectomy
Interventions
Chondrogen, Placebo
Drug
Lead sponsor
Mesoblast International Sàrl
Industry
Eligibility
18 Years to 60 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Indianapolis, Indiana • Bloomington, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 1, 2026, 10:35 PM EDT
Terminated Phase 2 Interventional Results available

Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device

NCT03925324
View directory record Official record
Conditions
Ischemic Heart Disease, Non-ischemic Cardiomyopathy
Interventions
Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Placebo
Biological · Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 1, 2026, 10:35 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

hCT-MSCs for COVID19 ARDS

NCT04399889
View directory record Official record
Conditions
COVID, Corona Virus Infection, COVID19
Interventions
Human cord tissue mesenchymal stromal cells (hCT-MSC) manufactured by Duke University., Placebo
Biological · Other
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boca Raton, Florida • Miami, Florida • Valhalla, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 1, 2026, 10:35 PM EDT
Completed Phase 2 Interventional

Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease

NCT00294112
View directory record Official record
Conditions
Crohn's Disease
Interventions
Prochymal™ adult human mesenchymal stem cells, adult human mesenchymal stem cells
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Charlotte, North Carolina • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Oct 1, 2026, 10:35 PM EDT
Not listed Phase 2 Interventional

Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II)

NCT04847739
View directory record Official record
Conditions
Perianal Fistula, Crohn's Disease
Interventions
Seton Placement, AVB-114
Procedure · Drug
Lead sponsor
Avobis Bio, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Redwood City, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 1, 2026, 10:35 PM EDT
Recruiting Phase 2 Interventional

Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.

NCT07512362
View directory record Official record
Conditions
Mild Cognitive Impairment, Early Alzheimer's Disease, AD-MCI
Interventions
human Mesenchymal Stem Cells
Biological
Lead sponsor
Bernard (Barry) Baumel
Other
Eligibility
55 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 1, 2026, 10:35 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

NCT03822858
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Intrathecal MSC-NP injection
Drug
Lead sponsor
Tisch Multiple Sclerosis Research Center of New York
Other
Eligibility
18 Years to 70 Years
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 1, 2026, 10:35 PM EDT
Active, not recruiting Phase 1 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions
Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 1, 2026, 10:35 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

The Role of Amnion Membrane Allografts in Nipple Preservation

NCT06073808
View directory record Official record
Conditions
Mastectomy, Gender Affirmation Surgery, Nipple Sparing Mastectomy, Prophylactic Mastectomy, Benign Breast Condition
Interventions
AmnioFix dehydrated Human Amnion/Chorion Membrane Allograft, Control Device
Device
Lead sponsor
Stanford University
Other
Eligibility
15 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 1, 2026, 10:35 PM EDT
No Longer Available No phase listed Expanded access

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy

NCT04029896
View directory record Official record
Conditions
Cerebral Palsy
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
3 Years and older · Male only
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 1, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS

NCT03799718
View directory record Official record
Conditions
Multiple Sclerosis, Chronic Progressive
Interventions
NurOwn (MSC-NTF cells)
Biological
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Redwood City, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 1, 2026, 10:35 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS

NCT04681118
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
NurOwn (MSC-NTF cells)
Biological
Lead sponsor
Brainstorm-Cell Therapeutics
Industry
Eligibility
18 Years to 63 Years
U.S. locations
5
States / cities
Irvine, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 1, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure

NCT02032004
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Rexlemestrocel-L, Sham Comparator
Biological · Other
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
56
States / cities
Birmingham, Alabama • Gilbert, Arizona • Mesa, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 1, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

Bone Marrow Derived Mesenchymal Stem Cells in Improving Heart Function in Patients With Heart Failure Caused by Anthracyclines

NCT02408432
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure
Interventions
Laboratory Biomarker Analysis, Standard of Care, Mesenchymal Stem Cell Transplantation
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Oct 1, 2026, 10:35 PM EDT
Not listed Phase 2 Interventional

Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis

NCT04448106
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis Shoulder
Interventions
Celltex- AdMSCs
Biological
Lead sponsor
Celltex Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 1, 2026, 10:35 PM EDT
Suspended Phase 1 Interventional

MT2022-01: MSCs for ALD

NCT06030648
View directory record Official record
Conditions
Cerebral Adrenoleukodystrophy
Interventions
Mesenchymal stem cells (IV-MSC)
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 1, 2026, 10:35 PM EDT
Completed Early Phase 1 Interventional

Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation

NCT02468492
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Platelet Rich Plasma, Normal Saline
Biological · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
40 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 1, 2026, 10:35 PM EDT
Completed Phase 2 Interventional

Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

NCT02633163
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Low Dose Mesenchymal Stem Cells (MSCs), High Dose Mesenchymal Stem Cells (MSCs), Placebo Infusion
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 1, 2026, 10:35 PM EDT
Completed Phase 1 Interventional

Cord Blood Expansion on Mesenchymal Stem Cells

NCT00498316
View directory record Official record
Conditions
Myelodysplastic Syndrome, Leukemia
Interventions
Cord Blood Infusion, Busulfan, Fludarabine, Rituximab, ATG, Cyclophosphamide, Clofarabine, Total Body Irradiation (TBI), Melphalan, Tacrolimus, Mycophenolate Mofetil, G-CSF
Procedure · Drug · Other + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
1 Year to 80 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 1, 2026, 10:35 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

NCT00366145
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Prochymal®, Placebo, Standard of Care for GVHD
Biological · Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
6 Months to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Oct 1, 2026, 10:35 PM EDT
Terminated Phase 1 Interventional

Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds

NCT01751282
View directory record Official record
Conditions
Non Healing Wounds
Interventions
Stem Cell
Genetic
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 1, 2026, 10:35 PM EDT